Literature DB >> 33106623

Systemic mastocytosis with acute myeloid leukemia occurs from mutually exclusive clones expressing KITD816V and FLT3-ITD.

Jose-Mario Capo-Chichi1,2, Elizabeth Kagotho1, Rakesh Nayyar1, Davidson Zhao1, Mark Minden2, Hong Chang3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33106623     DOI： 10.1038/s41375-020-01073-5

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.

Authors:  M Jawhar; J Schwaab; S Schnittger; M Meggendorfer; M Pfirrmann; K Sotlar; H-P Horny; G Metzgeroth; S Kluger; N Naumann; C Haferlach; T Haferlach; P Valent; W-K Hofmann; A Fabarius; N C P Cross; A Reiter
Journal:  Leukemia       Date:  2015-10-14       Impact factor: 11.528

2.  Comprehensive mutational profiling in advanced systemic mastocytosis.

Authors:  Juliana Schwaab; Susanne Schnittger; Karl Sotlar; Christoph Walz; Alice Fabarius; Markus Pfirrmann; Alexander Kohlmann; Vera Grossmann; Manja Meggendorfer; Hans-Peter Horny; Peter Valent; Mohamad Jawhar; Martina Teichmann; Georgia Metzgeroth; Philipp Erben; Thomas Ernst; Andreas Hochhaus; Torsten Haferlach; Wolf-Karsten Hofmann; Nicholas C P Cross; Andreas Reiter
Journal:  Blood       Date:  2013-08-19       Impact factor: 22.113

3.  High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.

Authors:  Robert Fritsche-Polanz; Marika Fritz; Andrea Huber; Karl Sotlar; Wolfgang R Sperr; Christine Mannhalter; Manuela Födinger; Peter Valent
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

4.  Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).

Authors:  Karl Sotlar; Sema Colak; Anja Bache; Sabina Berezowska; Manuela Krokowski; Burkhard Bültmann; Peter Valent; Hans-Peter Horny
Journal:  J Pathol       Date:  2010-04       Impact factor: 7.996

5.  New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019.

Authors:  Michel Arock; Karl Sotlar; Jason Gotlib; Wolfgang R Sperr; Karin Hartmann; Lawrence B Schwartz; Cem Akin; Hans-Peter Horny; Peter Valent
Journal:  Leuk Lymphoma       Date:  2019-12-26

6.  Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers.

Authors:  Mohamad Jawhar; Juliana Schwaab; Nicole Naumann; Hans-Peter Horny; Karl Sotlar; Torsten Haferlach; Georgia Metzgeroth; Alice Fabarius; Peter Valent; Wolf-Karsten Hofmann; Nicholas C P Cross; Manja Meggendorfer; Andreas Reiter
Journal:  Blood       Date:  2017-04-19       Impact factor: 25.476

7.  KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.

Authors:  Mohamad Jawhar; Konstanze Döhner; Sebastian Kreil; Juliana Schwaab; Khalid Shoumariyeh; Manja Meggendorfer; Lambert L F Span; Stephan Fuhrmann; Nicole Naumann; Hans-Peter Horny; Karl Sotlar; Boris Kubuschok; Nikolas von Bubnoff; Karsten Spiekermann; Michael Heuser; Georgia Metzgeroth; Alice Fabarius; Stefan Klein; Wolf-Karsten Hofmann; Hanneke C Kluin-Nelemans; Torsten Haferlach; Hartmut Döhner; Nicholas C P Cross; Wolfgang R Sperr; Peter Valent; Andreas Reiter
Journal:  Leukemia       Date:  2019-01-11       Impact factor: 11.528
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.